Nanjing Well Pharmaceutical Co Ltd (603351) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥69.51 Million ≈ $10.17 Million USD) by net assets (CN¥1.77 Billion ≈ $258.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nanjing Well Pharmaceutical Co Ltd (603351) liquidity interval to measure how many days the company can operate on defensive assets alone.
Nanjing Well Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanjing Well Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Well Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jilin University Zhengyuan Info Tech
SHE:003029
|
-0.019x |
|
Summit Hotel Properties Inc
NYSE:INN
|
0.035x |
|
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
|
0.002x |
|
Icon Offshore Bhd
KLSE:5255
|
0.083x |
|
Guangzhou Boji Medical and Biotechnological Co Ltd
SHE:300404
|
-0.007x |
|
Songz Automobile Air Conditioning Co Ltd
SHE:002454
|
0.014x |
|
Shenzhen Longli Technology Co Ltd Class A
SHE:300752
|
0.018x |
|
Ginkgo Bioworks Holdings
NYSE:DNA
|
-0.105x |
Annual Cash Flow Conversion Efficiency for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 603351 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.71 Billion ≈ $249.96 Million |
CN¥221.79 Million ≈ $32.46 Million |
0.130x | +71.98% |
| 2023-12-31 | CN¥1.59 Billion ≈ $233.06 Million |
CN¥120.24 Million ≈ $17.60 Million |
0.075x | +2.69% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.92 Million |
CN¥108.99 Million ≈ $15.95 Million |
0.074x | +982.90% |
| 2021-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
CN¥-11.54 Million ≈ $-1.69 Million |
-0.008x | -111.60% |
| 2020-12-31 | CN¥1.30 Billion ≈ $190.18 Million |
CN¥93.30 Million ≈ $13.65 Million |
0.072x | -31.29% |
| 2019-12-31 | CN¥1.24 Billion ≈ $181.63 Million |
CN¥129.69 Million ≈ $18.98 Million |
0.104x | +0.72% |
| 2018-12-31 | CN¥614.61 Million ≈ $89.94 Million |
CN¥63.76 Million ≈ $9.33 Million |
0.104x | -22.45% |
| 2017-12-31 | CN¥532.80 Million ≈ $77.96 Million |
CN¥71.27 Million ≈ $10.43 Million |
0.134x | -53.67% |
| 2016-12-31 | CN¥443.99 Million ≈ $64.97 Million |
CN¥128.18 Million ≈ $18.76 Million |
0.289x | +4.79% |
| 2015-12-31 | CN¥294.49 Million ≈ $43.09 Million |
CN¥81.14 Million ≈ $11.87 Million |
0.276x | -11.25% |
| 2014-12-31 | CN¥240.35 Million ≈ $35.17 Million |
CN¥74.62 Million ≈ $10.92 Million |
0.310x | -- |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; bi… Read more